

ACTIVE CEPI-FUNDED VACCINE CANDIDATE PORTFOLIO BY PHASE







	Preclinical	Phase I	Phase II	Phase IIb/III & III	Registration
Lassa fever	University of Oxford		IAVI		
MERS	Uvax	IDT, Barinthus/University of Oxford			
Nipah		PHV, University of Oxford			
Rift Valley fever	UC Davis, Afrigen	Wageningen U., University of Oxford and KEMRI – Wellcome Trust			
Chikungunya				IVI/Bharat	Valveva
COVID-19*					SK Bioscience, Biological E, Moderna, Clover, Novavax, AZ/Oxford, University of Hong Kong
Broadly protective Betacoronavirus (BPBC)	MigVax, VIDO, IVI, CPI/CalTech, Bharat/U Syd/ExcellGene, NEC, SK Bioscience, Intravacc, Panacea/THSTI	VBI			

(*) CEPI has also funded booster studies of SARS-CoV-2 vaccines developed by Medigen and Vaxxinity

	Preclinical		Phase I	Phase II	Phase IIb/III & III	Registration
Disease X	Akagera	Tiba bio	BioNTech			
	Chungbuk University	Gennova*	Lemonex			
	University of Queensland	Celestial				
	Moderna	Emervax				
	SK bio	HMRI				
	University of Oxford	Imperial				
	Curevac	Amplitude				
	Boost Biopharma	Nagasaki University				
	Centivax	VitriVax				

(*) Gennova funding supports platform optimisation and development of candidate vaccines against Rabies and Nipah virus.



All .

DISEASE	DEVELOPER	PHASE	PLATFORM	CEPI FUNDING (IN USD)
 Lassa fever	University of Oxford	Preclinical	Viral Vector	Up to \$19 million‡
	IAVI	Phase 2	Viral Vector	Up to \$64.4 million
 MERS	University of Oxford + Barinthus	Phase I	Viral vector	Up to \$47 million‡
	IDT	Phase I	Viral vector	Up to \$36 million
	Uvax bio	Preclinical	Nanoparticle	Up to \$2.6 million
 Nipah	University of Oxford	Phase I	Viral Vector	Up to \$19 million‡
	PHV	Phase I	Viral vector	Up to \$43.6 million
 Rift Valley fever	UC Davis	Preclinical	Live attenuated	Up to \$40 million
	Wageningen University	Phase I	Live attenuated	Up to \$38.4 million
	University of Oxford and KEMRI-Wellcome Trust	Phase I	Viral Vector	Up to \$3.7 million
	Afrigen	Preclinical	RNA	Up to \$6.2 million
 Chikungunya	IVI/Bharat	Phase IIb/III	Inactivated	Up to \$14.1 million
	Valneva	Registration	Live attenuated	Up to \$65.9 million
 COVID-19	SK Bioscience	Registration	Protein based	Up to \$210 million
	Biological E	Registration	Protein based	Up to \$14 million
	Moderna	Registration	Protein based	Up to \$1 million
	Clover	Registration	Protein based	Up to \$397.4 million
	AZ/University of Oxford	Registration	Viral vector	Up to \$384 million
	Novavax	Registration	Protein based	Up to \$399 million

(‡) Includes Lassa, MERS and Nipah funding

(**) Includes COVID-19 variant and BPBC funding. Project funding complete.

Rift Valley fever, Chikungunya, and some COVID-19 and other projects are supported by European Commission co-funding.

 Broadly protective Beta-coronavirus (BPBC)	MigVax	Preclinical	Protein based	Up to \$4.3 million
	BioNet	Preclinical	RNA	Up to \$16.9 million
	VIDO	Preclinical	Protein based	Up to \$22 million
	Bharat/ U Sydney/ ExcellGene	Preclinical	Protein based	Up to \$19.9 million
	CPI/Caltech	Preclinical	Protein based	Up to \$30 million
	NEC	Preclinical	RNA	Up to \$4.8 million
	SK Bioscience	Preclinical	Protein based	Up to \$50 million
	Panacea/THSTI	Preclinical	Protein based	Up to \$12.5 million
	Intravacc	Preclinical	Protein based	Up to \$4.8 million
 Disease X	Akagera	Preclinical	RNA	Up to \$1.5 million
	Amplitude	Preclinical	RNA	Up to \$1 million
	BioNTech	Phase I	RNA	Up to \$90 million
	Boost Biopharma	Preclinical	Protein based	Up to \$5 million
	Celestial	Preclinical	RNA	Up to \$0.7 million
	Centivax	Preclinical	RNA	Up to \$5.0 million
	Chungbuk National University	Preclinical	RNA	Up to \$0.9 million
	Curevac	Preclinical	RNA	Up to \$34 million
	Emervax	Preclinical	RNA	Up to \$2.2 million
	Genova	Preclinical	RNA	Up to \$16.98 million##
	HMRI	Preclinical	RNA	Up to \$3.8 million
	Imperial College London	Preclinical	RNA	Up to \$8.4 million
	Lemonex	Phase I	RNA	Up to \$4.9 million
	Moderna	Preclinical	RNA	Not yet at a stage where CEPI provides funding to Moderna.
	Nagasaki University	Preclinical	RNA	Up to \$5 million
	University of Oxford	Preclinical	Viral Vector	Up to \$80 million
University of Queensland	Preclinical	Protein based	Up to \$10.6 million	
SK Bioscience	Preclinical	RNA	Up to \$40 million	
Tiba Bio	Preclinical	RNA	Up to \$2 million	
VitriVax	Preclinical	ALTA®	Up to \$5 million	

(##) Includes \$13.38 million for funding a Nipah candidate and \$3.6 for funding for a Rabies candidate/platform optimisation.